Firas El Chaer, MD, is a hematology and medical oncology specialist and an assistant professor of medicine at the University of Virginia, Emily Couric Clinical Cancer Center. In addition to specializing in infectious diseases in immunocompromised patients with cancer, Dr. El Chaer focuses on hematologic malignancies and stem cell transplantation. He has also been working on improving the outcomes for acute leukemias in adults by focusing on targeted therapies and overcoming resistance mechanisms. Dr. El Chaer currently serves on the Advisory Committee for the ACCC Multidisciplinary Acute Lymphocytic Leukemia Care education program.
Dr. El Chaer recently spoke to ACCCBuzz about his top takeaways from the December 2019 American Society of Hematology (ASH) Annual Meeting. Here he discusses what he believes to be the most important issues and trends affecting the cancer care community.
ACCCBuzz: What ongoing trends in cancer treatment were most often discussed at this ASH conference?
Dr. El Chaer: We are increasingly incorporating targeted therapies with old-school chemotherapy treatments. What stood out in this ASH was the increasing effort to move targeted treatments into the front-line setting, especially with acute lymphoblastic leukemia (ALL) and all acute leukemias. In particular, with ALL there are a lot of advances in the field of CAR-T therapy as well as in the minimum residual disease therapy guidelines.
When a new leukemia patient presents at a teaching hospital, you now send them to genomic testing, and patients are stratified into different treatment strategies based on their test results. This is particularly the case for ALL patients.
ACCCBuzz: How should the multidisciplinary cancer care team approach the side effects of precision therapies?
Dr. El Chaer: UVA has adopted standard operating procedures (SOPs)—internal guidelines on how to approach anything regarding precision therapies, from administering drugs to side effects. SOPs are usually multidisciplinary. It’s essential to have easy access to peer-reviewed, well-thought out SOPs, so you minimize the risk of mistakes as well as provide a standard of care for all members of the cancer care team.
ACCCBuzz: With the advent of effective immunotherapies such as the new checkpoint inhibitors and CAR-T therapy, is chemotherapy a thing of the past?
Dr. El Chaer: Although there is so much talk about targeted, precision therapies right now, it’s important to remember that traditional chemotherapy is not going to go away any time soon. However, with the benefit of today’s targeted therapies, we can definitely provide additional improvement to what we have accomplished in the past decades in oncology care. Traditional treatments are here to stay for most diseases, but they are being improved by using them in conjunction with targeted therapies.
ACCCBuzz: What practical implications might these emerging treatments have on the multidisciplinary cancer care team?
Dr. El Chaer: Because these therapies are not traditional chemotherapy, they come with a substantial list of side effects that the whole cancer care team should be aware of and know how to manage.
Another significant challenge is the cost of these treatments. It is particularly important that social workers and case managers know about this issue. If patients cannot access them, all of these clinical enhancements go to waste. These drugs are effective and are being approved by the FDA, but access to them is significantly hindered by high copays, or, if patients are not adequately insured, the cost of the medications themselves.
We try to get access to grants to cover the copays, either from the Leukemia and Lymphoma Society or other cancer societies that also have dedicated grants for these therapies. Or we try to obtain copay cards from pharma companies. But this is not ideal. The market prices are exorbitantly high and not sustainable regardless of how much insurance or Medicare is able to cover.
*****
Below, Dr. El Chaer shares what he believes to be some of the most important clinical developments in acute lymphoblastic leukemia presented at the 2019 ASH conference.
Chemotherapy in combination with a tyrosine kinase inhibitor (TKI) is the standard of care for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) with a 5-year overall survival 35-50%. ABL1 mutations (i.e. T315I) are the main mechanism of relapse. Ponatinib, a third-generation TKI, is active against T315I. HyperCVAD in combination with ponatinib is associated with high response rates but long-term efficacy is unknown.
In this study, 86 patients, median age 46 years old (range 21-80) with Ph(+) ALL, received £2 courses of prior chemotherapy without clinically significant cardiovascular disease or venous thromboembolism. Ponatinib was given at 45mg during induction, then at 30mg starting at cycle 2 with further reduction to 15mg once complete molecular response was achieved.
With a median follow-up of 43 months, the 3-year continuous complete remission (CR), event-free survival (EFS) and overall survival (OS) rates were 84%, 70%, and 78%, respectively. Three patients had relapsed disease while on ponatinib and two were found to have an E255K ABL kinase domain mutation. The 3-year OS rate was 66% for patients who underwent hematopoietic stem cell transplantation (HSCT) and 90% for patients who did not undergo HSCT (p=0.07). Currently ongoing studies are evaluating ponatinib and blinatumomab +/- low-intensity chemotherapy for Ph(+) ALL.
This was a multicenter frontline chemo-free induction consolidation phase II trial (D-ALBA, GIMEMA LAL2116) with the combination of a second generation TKI dasatinib with blinatumomab for adult patients with Ph(+) ALL. Prior to dasatinib, patients received a 7-day steroids pre-phase and continued until D+31. Dasatinib (140mg/day) was administered for 85 consecutive days. Thereafter, patients who obtained a complete hematologic response received a post-induction consolidation with blinatumomab at a flat dose of 28 mg/day. Dasatinib was continued during treatment with blinatumomab.
Sixty-three patients were enrolled with median age 55 years old (range 24-82), and 47 have completed the 2nd cycle of blinatumomab (the primary endpoint) and 56% had a molecular response. The 12-month OS and disease-free survival (DFS) are 94.2% and 87.8%, respectively. ABL1 mutational analysis in 15 patients with evidence of a MRD increase and mutations were detected in 7 patients. All mutations but 1 occurred prior to the start of blinatumomab and all were cleared by blinatumomab.
In this first chemo-free induction-consolidation protocol for adult Ph(+) ALL patients, the rates of molecular responses and survival were highly promising.
With a lentiviral transduction of a bivalent CAR construct incorporating the fmc63 CD19 and m971 CD22 scFvs and a 41BB costimulatory endodomain. Dose level 1 was 1x106 CART cells/kg and dose level 2 was 3x106 cells/kg. Primary objectives assessed the ability to successfully manufacture CD19/CD22 CART cells and safety while response at D+28 post-infusion was a secondary objective.
Nineteen patients have been enrolled (10 pediatric and 9 adults) with a median of 4 (range 2-11) prior lines of leukemia-directed therapy, with 10 patients received prior HSCT, 9 treated with prior blinatumomab, 3 with prior CD19 directed CART cells and 4 with prior Inotuzumab. Of the 14 patients who have been infused to date, 12 patients have reached D+28. 92% achieved CR, 10 of whom achieved CR at D+28. 75% experienced CRS and 17% had ICANS. Only one patient had grade 4 CRS and ICANS, both of which were reversible. To date, 3 patients had their disease relapse, all with retention of CD19 antigen. The OS for all infused patients was 92% with a median follow-up of 9.5 months.
This phase I trials of bispecific CD19/CD22 targeting CART cells in R/R ALL demonstrated safety and tolerability at two dose levels, expanded accrual at dose level 2 is ongoing.
The combination of inotuzumab with reduced-intensity mini-hyper-CVD chemotherapy in older adults with newly diagnosed ALL is safe and highly effective. The addition of blinatumomab to this regimen may further improve outcomes. In this trial, patients ³60 years of age with newly diagnosed Philadelphia chromosome neg pre-B-cell ALL received mini-Hyper-CVD for up to 8 cycles. After protocol amendment to decrease risk of venoocclusive disease, inotuzumab was added in fractionated doses each cycle (0.6 mg/m2 on day 2 and 0.3 mg/m2 on day 8 of cycle 1; 0.3 mg/m2 on day 2 and 8 of cycles 2-4) and 4 cycles of blinatumomab were administered following 4 cycles of hyper-CVD plus inotuzumab, followed by maintenance with 12 cycles of POMP and 4 cycles of blinatumomab (1 cycle of blinatumomab after every 3 cycles of POMP).
Median age was 68 years and 28% of patients had their disease positive for TP53 mutation. 19% were CRLF2 positive, and 27% had adverse-risk karyotype. 33/58 pts (57%) were CD20+ and received rituximab. Among 59 patients evaluable for morphologic response, 58 (98%) responded (CR, n=51; CRp, n=6; CRi, n=1). Measurable residual disease (MRD) negativity by 6-color flow cytometry was achieved in 48/62 pts (77%) after 1 cycle and 59/63 pts (94%) overall. There were no early deaths, and the 30-day and 60-day mortality rates were 0% and 3%, respectively.
The 3-year continuous remission rate was 69% and 87% for patients age 60-69 and ≥70 years, respectively (P=0.25), and the 3-year OS rate was 63% and 42%, respectively (P=0.13). The trend for worse survival in the patients ≥70 years was driven predominantly by the increased rate of death in CR/CRp in this older group.
The achievement of CMR predicts better outcomes in Ph(+) ALL. The lack of CMR and major molecular response (MMR) at 3 months confer poor outcomes. The investigators reviewed 204 patients with newly diagnosed Ph(+) ALL treated with hyper-CVAD in combination with TKI, of whom 94 (46%) did not achieve a 3-month CMR. Overall, allogeneic stem cell transplantation (allo-HSCT) was performed in 30% of the patients. In multivariate analysis, 3-month MMR predicted longer PFS (p<0.01) and OS (p=0.01).
A 5-month landmark analysis was performed to assess the effect of allo-HSCT on survival by 3-month MMR status. In patients who achieved 3-month MMR, 5-year PFS and OS rates were 60% and 58% (p=0.64) and 64% and 64% (p=0.73) in patients with and without allo-HSCT, respectively. In contrast, among patients who did not achieve a 3-month MMR, there was a tendency for better PFS (5-PFS, 43% vs 21%; p=0.25) and OS (5-year OS, 43% vs. 26%; p=0.57) in favor of allo-HSCT.
The lack of achievement of MMR at 3 months predicted worse outcomes in Ph+ ALL. Higher survival rates were seen when allo-HSCT was performed in patients who do not achieve 3-month MMR.
This is a phase I multicenter, open-label, dose escalation study with R/R ALL or lymphoblastic lymphoma (LLy) where 36 patients received daily venetoclax in addition to navitoclax (a BCL-2/BCL-XL/BCL-W inhibitor) from day 3 onward.
The overall response rate (ORR) was 56% (20/36) in the total population, with best responses of complete response (CR)/CR with incomplete marrow recovery (CRi)/CR with incomplete platelet recovery (CRp) in 18 patients. Of the 18 patients with CR/CRi/CRp, 10 (56%) had undetectable MRD. Venetoclax + navitoclax in combination with chemotherapy is well tolerated, with few discontinuations or dose reductions from adverse events in patients with R/R ALL or LLy.
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
